SCHEMBL202163

SCHEMBL202163

FC(F)(F)Oc1ccccc1-c1noc(CBr)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.51
DPP4 P27487 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
HCRTR1 O43613 4/20 0.41
HCRTR2 O43614 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PLAT P00750 2/20 0.40
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29828612 0.83 S1PR1 (0.49) S1PR1DPP4DPP7SMN1; SMN2ALDH1A1
SCHEMBL6042179 0.82 SMN1; SMN2 (0.60) S1PR1CASP3SENP8SENP7SENP6
SCHEMBL30098391 0.82 SMN1; SMN2 (0.60) S1PR1CASP3SENP8SENP7SENP6
Hydrochloric Acid SCHEMBL29096778 0.82 S1PR1 (0.48) S1PR1DPP4DPP7SMN1; SMN2ALDH1A1
SCHEMBL104245 0.80 S1PR1 (0.46) S1PR1DPP4DPP7CASP3SENP8
SCHEMBL6327861 0.79 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1TP53L3MBTL1LMNA
SCHEMBL30872201 0.79 ALDH1A1 (0.44) CASP3SENP8SENP7SENP6SMN1; SMN2
SCHEMBL28579413 0.79 ALDH1A1 (0.44) CASP3SENP8SENP7SENP6SMN1; SMN2
SCHEMBL15495297 0.78 S1PR1 (0.61) S1PR1DPP4DPP7HCRTR1HCRTR2
SCHEMBL28869666 0.77 NPC1 (0.50) SMN1; SMN2NPC1ALDH1A1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 S1PR1 776/4885DPP4 1700/4885DPP7 1638/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 S1PR1 405/4885DPP4 2954/4885DPP7 2716/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 S1PR1 993/4885DPP4 1939/4885DPP7 1816/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 S1PR1 405/4885DPP4 2954/4885DPP7 2716/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 S1PR1 405/4885DPP4 2954/4885DPP7 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.